The pathobiological impact of cigarette smoke on pancreatic cancer development (Review)

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 5-14

  Wittel, Uwe A ^a   Momi, Navneet ^b   Seifert, Gabriel ^a   Wiech, Thorsten ^a   Hopt, Ulrich T ^a   Batra, Surinder K ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Carcinogenesis; Carcinogens; Chronic pancreatitis; Cigarette smoke; Nicotine; nnk; Pancreatic cancer

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; 2,6 DIMETHYL 4 NITROSOMORPHOLINE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 5,6 EPOXY 7 HYDROXYMETHYL 12 METHYLBENZANTHRACENE; 7,12 DIMETHYL 1,2 BENZANTHRACENE 3 METHYLCHOLANTHRENE; BIS(2 ACETOXYPROPYL)NITROSAMINE; BIS(2 HYDROXYPROPYL)NITROSAMINE; BIS(2 OXOPROPYL)NITROSAMINE; CIGARETTE SMOKE; CYCLIC AMP; CYCLOOXYGENASE 2; DIMETHYLBENZ[A]ANTHRACENE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLNITROSOUREA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; N ACETONYL N (2 HYDROXYPROPYL)NITROSAMINE; N NITROSOMETHYL (2 OXOPROPYL)AMINE; NICOTINE; NOTCH RECEPTOR; PANCREAS ENZYME; PROSTAGLANDIN E2; PROTEIN BCL 2; TOBACCO SMOKE; UNCLASSIFIED DRUG;

ACINAR CELL; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENESIS; CELL DAMAGE; CELL LINEAGE; CIGARETTE SMOKING; DNA ADDUCT; DNA DAMAGE; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOGENESIS; PANCREAS JUICE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ACINAR CELLS; ANIMALS; CARCINOGENS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NICOTINE; PANCREAS; PANCREATIC NEOPLASMS; RISK FACTORS; SMOKE; TOBACCO;

EID: 84862870020     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1414     Document Type: Review

References (178)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Lowenfels AB and Maisonneuve P: Risk factors for pancreatic cancer. J Cell Biochem 95: 649-656, 2005. (Pubitemid 41420153)
3. Bray F, Sankila R, Ferlay J and Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38: 99-166, 2002. (Pubitemid 34031832)
4. Ries LAG, Harkins D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, USA. Section 22, pp5-6, 2006.
5. Michaud DS: Epidemiology of pancreatic cancer. Minerva Chir 59: 99-111, 2004.
6. Everhart J and Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273: 1605-1609, 1995.
7. Silverman DT, Schiffman M, Everhart J, et al: Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80: 1830-1837, 1999. (Pubitemid 29389642)
8. Hennig R, Ding XZ and Adrian TE: On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 19: 999-1011, 2004. (Pubitemid 38855079)
9. Wang F, Gupta S and Holly EA: Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 15: 1458-1463, 2006. (Pubitemid 44299315)
10. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andade M and Petersen GM: Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134: 95-101, 2008. (Pubitemid 350309328)
11. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM and Chari ST: Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134: 981-987, 2008. (Pubitemid 351451984)
12. Pannala R, Basu A, Petersen GM and Chari ST: New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10: 88-95, 2009.
13. Kolb A, Rieder S, Born D, et al: Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biol Ther 8: 1527-1533, 2009.
14. Stevens RJ, Roddam AW and Beral V: Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 96: 507-509, 2007. (Pubitemid 46215224)
15. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J and Albanes D: Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294: 2872-2878, 2005. (Pubitemid 41785868)
16. Rousseau MC, Parent ME, Pollak MN and Siemiatycki J: Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 118: 2105-2109, 2006.
17. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M and Petersen GM: Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129: 504-511, 2005. (Pubitemid 41096638)
18. Larsson SC, Orsini N and Wolk A: Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 120: 1993-1998, 2007. (Pubitemid 46418379)
19. Lin Y, Kikuchi S, Tamakoshi A, et al: Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer 120: 2665-2671 2007. (Pubitemid 46651289)
20. Rapp K, Schroeder J, Klenk J, et al: Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 93: 1062-1067, 2005. (Pubitemid 41548403)
21. Larsson SC, Permert J, Hakansson N, Naslund I, Bergkvist L and Wolk A: Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer 93: 1310-1315, 2005. (Pubitemid 41679420)
22. Nothlings U, Wilkens LR, Murphy SP, Hankin JH, Henderson BE and Kolonel LN: Body mass index and physical activity as risk factors for pancreatic cancer: the Multiethnic Cohort Study. Cancer Causes Control 18: 165-175, 2007. (Pubitemid 46215313)
23. Lee IM, Sesso HD, Oguma Y and Paffenbarger RS Jr: Physical activity, body weight, and pancreatic cancer mortality. Br J Cancer 88: 679-683, 2003. (Pubitemid 36411443)
24. Khurana V, Sheth A, Caldito G and Barkin JS: Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 34: 260-265, 2007. (Pubitemid 46294804)
25. Li D, Yeung SC, Hassan MM, Konopleva M and Abbruzzese JL: Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137: 482-488, 2009.
26. Malka D, Hammel P, Maire F, et al: Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 51: 849-852, 2002. (Pubitemid 35408607)
27. Talamini G, Falconi M, Bassi C, et al: Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 94: 1253-1260, 1999. (Pubitemid 29214638)
28. Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328: 1433-1437, 1993. (Pubitemid 23143844)
29. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J and Whitcomb DC: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89: 442-446, 1997. (Pubitemid 27136736)
30. Chari ST, Mohan V, Pitchumoni CS, Viswanathan M, Madanagopalan N and Lowenfels AB: Risk of pancreatic carcinoma in tropical calcifying pancreatitis: an epidemiologic study. Pancreas 9: 62-66, 1994. (Pubitemid 24007351)
31. Greer JB and Whitcomb DC: Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 9: 411-418, 2009.
32. Lowenfels AB and Maisonneuve P: Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 197-209, 2006.
33. Klein AP, Brune KA, Petersen GM, et al: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64: 2634-2638, 2004. (Pubitemid 38523922)
34. Greer JB and Whitcomb DC: Role of BRCA1/2 mutations in pancreatic cancer. Gut 56: 601-605, 2006.
35. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95: 214-221, 2003. (Pubitemid 36240634)
36. Couch FJ, Johnson MR, Rabe KG, et al: The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16: 342-346, 2007. (Pubitemid 46383356)
37. Habbe N, Langer P, Sina-Frey M and Bartsch DK: Familial pancreatic cancer syndromes. Endocrinol Metab Clin North Am 35: 417-430, xi, 2006.
38. Pogue-Geile KL, Chen R, Bronner MP, et al: Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3: e516, 2006.
39. Bradbury J: Familial pancreatic-cancer gene found. Lancet Oncol 8: 14, 2007.
40. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ and Calle EE: Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev 14: 459-466, 2005. (Pubitemid 40270112)
41. Qiu D, Kurosawa M, Lin Y, et al: Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J Epidemiol 15 (Suppl. 2): S157-S167, 2005. (Pubitemid 41410098)
42. Fuchs CS, Colditz GA, Stampfer MJ, et al: A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 156: 2255-2260, 1996. (Pubitemid 26361920)
43. Yun JE, Jo I, Park J, et al: Cigarette smoking, elevated fasting serum glucose, and risk of pancreatic cancer in Korean men. Int J Cancer 119: 208-212, 2006.
44. IARC: Tobacco smoke and involuntary smoking. Lyon, France, 83: 1187, 2004.
45. Rulyak SJ, Lowenfels AB, Maisonneuve P and Brentnall TA: Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 124: 1292-1299, 2003. (Pubitemid 36531804)
46. Lowenfels AB, Maisonneuve P and Whitcomb DC: Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am 84: 565-573, 2000. (Pubitemid 30346152)
47. Lin Y, Tamakoshi A, Hayakawa T, Ogawa M and Ohno Y: Cigarette smoking as a risk factor for chronic pancreatitis: a case-control study in Japan. Research Committee on Intractable Pancreatic Diseases. Pancreas 21: 109-114, 2000. (Pubitemid 30612849)
48. Yadav D, Hawes RH, Brand RE, et al: Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med 169: 1035-1045, 2009.
49. Maisonneuve P, Lowenfels AB, Mullhaupt B, et al: Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. Gut 54: 510-514, 2005. (Pubitemid 40395503)
50. Maisonneuve P, Frulloni L, Mullhaupt B, Faitini K, Cavallini G, Lowenfels AB and Ammann RW: Impact of smoking on patients with idiopathic chronic pancreatitis. Pancreas 33: 163-168, 2006. (Pubitemid 44174564)
51. Maisonneuve P and Lowenfels AB: Chronic pancreatitis and pancreatic cancer. Dig Dis 20: 32-37, 2002.
52. Tobacco related exposures. In: Report on Carcinogens. 11th edition. US Department of Health and Human Services, Public Health Service, National Toxicology Program, 2005.
53. Longnecker DS, Shinozuka H and Dekker A: Focal acinar cell dysplasia in human pancreas. Cancer 45: 534-540, 1980. (Pubitemid 10169302)
54. Kishi K, Nakamura K, Yoshimori M, et al: Morphology and pathological significance of focal acinar cell dysplasia of the human pancreas. Pancreas 7: 177-182, 1992.
55. Tanaka T, Mori H and Williams GM: Atypical and neoplastic acinar cell lesions of the pancreas in an autopsy study of Japanese patients. Cancer 61: 2278-2285, 1988.
56. Fang J, Hussong J, Roebuck BD, Talamonti MS and Rao MS: Atypical acinar cell foci in human pancreas. Morphological and morphometric analysis. Int J Pancreatol 22: 127-130, 1997. (Pubitemid 27500567)
57. Shinozuka H, Lee RE, Dunn JL and Longnecker DS: Multiple atypical acinar cell nodules of the pancreas. Hum Pathol 11: 389-391, 1980. (Pubitemid 10032510)
58. Bockman DE, Guo J, Buchler P, Muller MW, Bergmann F and Friess H: Origin and development of the precursor lesions in experimental pancreatic cancer in rats. Lab Invest 83: 853-859, 2003. (Pubitemid 36723694)
59. Auerbach O and Garfinkel L: Histologic changes in pancreas in relation to smoking and coffee-drinking habits. Dig Dis Sci 31: 1014-1020, 1986. (Pubitemid 16025635)
60. Tomioka T, ndren-Sandberg A, Fujii H, Egami H, Takiyama Y and Pour PM: Comparative histopathological findings in the pancreas of cigarette smokers and non-smokers. Cancer Lett 55: 121-128, 1990.
61. Wittel UA, Pandey KK, Andrianifahanana M, et al: Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am J Gastroenterol 101: 148-159, 2006. (Pubitemid 43381723)
62. Shi MM, Chong IW, Long NC, Love JA, Godleski JJ and Paulauskis JD: Functional characterization of recombinant rat macrophage inflammatory protein-1 alpha and mRNA expression in pulmonary inflammation. Inflammation 22: 29-43, 1998. (Pubitemid 28065856)
63. Rau B, Paszkowski A, Lillich S, Baumgart K, Moller P and Beger HG: Differential effects of caspase-1/interleukin-1beta-converting enzyme on acinar cell necrosis and apoptosis in severe acute experimental pancreatitis. Lab Invest 81: 1001-1013, 2001. (Pubitemid 32645976)
64. Rane SG, Lee JH and Lin HM: Transforming growth factor-beta pathway: role in pancreas development and pancreatic disease. Cytokine Growth Factor Rev 17: 107-119, 2006. (Pubitemid 43117520)
65. Wittel UA, Singh AP, Henley BJ, Andrianifahanana M, Akhter MP, Cullen DM and Batra SK: Cigarette smoke-induced differential expression of the genes involved in exocrine function of the rat pancreas. Pancreas 33: 364-370, 2006. (Pubitemid 44690726)
66. Bynum TE, Solomon TE, Johnson LR and Jacobson ED: Inhibition of pancreatic secretion in man by cigarette smoking. Gut 13: 361-365, 1972.
67. Demol P, Singer MV, Hotz J, Dipp M and Goebell H: Interdigestive gastrointestinal motility and secretion of gastric acid and pancreatic enzymes in young cigarette smokers. Digestion 29: 107-111, 1984. (Pubitemid 14137986)
68. Balldin G, Borgstrom A, Eddeland A, Genell S, Hagberg L and Ohlsson K: Elevated serum levels of pancreatic secretory proteins in cigarette smokers after secretin stimulation. J Clin Invest 66: 159-162, 1980. (Pubitemid 10071360)
69. Andriulli A, Masoero G, Amato A, et al: Serum immunoreactive cationic trypsinogen response to secretin in normal subjects. Am J Gastroenterol 78: 579-583, 1983. (Pubitemid 13000945)
70. Munch R, Kehl O, Buhler H, Medici T and Ammann R: [Changes in the serum pancreas enzyme following i.v. stimulation with secretin in subjects with a normal pancreas]. Schweiz Med Wochenschr 117: 756-760, 1987.
71. Dubick MA, Conteas CN, Billy HT, Majumdar AP and Geokas MC: Raised serum concentrations of pancreatic enzymes in cigarette smokers. Gut 28: 330-335, 1987. (Pubitemid 17039055)
72. Sliwinska-Mosson M and Milnerowicz H: [Influence of tobacco smoking on lipase activity in patients with pancreatitis]. Przegl Lek 62: 1058-1061, 2005.
73. Borissova AM, Tankova T, Kirilov G, Dakovska L and Krivoshiev S: The effect of smoking on peripheral insulin sensitivity and plasma endothelin level. Diabetes Metab 30: 147-152, 2004. (Pubitemid 38715170)
74. Milnerowicz H, Sliwinska-Mosson M, Rabczynski J, Nowak M and Milnerowicz S: Dysfunction of the pancreas in healthy smoking persons and patients with chronic pancreatitis. Pancreas 34: 46-54, 2007. (Pubitemid 46045720)
75. Owyang C and Logsdon CD: New insights into neurohormonal regulation of pancreatic secretion. Gastroenterology 127: 957-969, 2004. (Pubitemid 39208427)
76. Saluja A, Logsdon C and Garg P: Direct versus indirect action of cholecystokinin on human pancreatic acinar cells: is it time for a judgment after a century of trial? Gastroenterology 135: 357-360, 2008.
77. 2+ signaling and enzyme secretion by cholecystokinin in human pancreatic acinar cells. Gastroenterology 135: 632-641, 2008.
78. Samuel I, Zaheer A, Zaheer S and Fisher RA: Bile-pancreatic juice exclusion increases cholinergic M3 and CCK-A receptor expression and interleukin-6 production in ligation-induced acute pancreatitis. Am J Surg 188: 511-515, 2004. (Pubitemid 39491095)
79. Chowdhury P, MacLeod S, Udupa KB and Rayford PL: Pathophysiological effects of nicotine on the pancreas: an update. Exp Biol Med 227: 445-454, 2002.
80. Doi R, Chowdhury P, Nishikawa M, Takaori K, Inoue K, Imamura M and Rayford PL: Carbachol and cholecystokinin enhance accumulation of nicotine in rat pancreatic acinar cells. Pancreas 10: 154-160, 1995.
81. Chowdhury P and Udupa KB: Nicotine as a mitogenic stimulus for pancreatic acinar cell proliferation. World J Gastroenterol 12: 7428-7432, 2006. (Pubitemid 46017738)
82. Chowdhury P and Walker A: A cell-based approach to study changes in the pancreas following nicotine exposure in an animal model of injury. Langenbecks Arch Surg 393: 547-555, 2008.
83. Chowdhury P, Doi R, Tangoku A and Rayford PL: Structural and functional changes of rat exocrine pancreas exposed to nicotine. Int J Pancreatol 18: 257-264, 1995. (Pubitemid 26023508)
84. Lindkvist B, Wierup N, Sundler F and Borgstrom A: Long-term nicotine exposure causes increased concentrations of trypsinogens and amylase in pancreatic extracts in the rat. Pancreas 37: 288-294, 2008.
85. Chowdhury P, Hosotani R and Rayford PL: Inhibition of CCK or carbachol-stimulated amylase release by nicotine. Life Sci 45: 2163-2168, 1989. (Pubitemid 19283026)
86. Lau PP, Dubick MA, Yu GS, Morrill PR and Geokas MC: Dynamic changes of pancreatic structure and function in rats treated chronically with nicotine. Toxicol Appl Pharmacol 104: 457-465, 1990. (Pubitemid 20262474)
87. Bose C, Zhang H, Udupa KB and Chowdhury P: Activation of p-ERK1/2 by nicotine in pancreatic tumor cell line AR42J: effects on proliferation and secretion. Am J Physiol Gastrointest Liver Physiol 289: G926-G934, 2005. (Pubitemid 41532586)
88. Chowdhury P, Bose C and Udupa KB: Nicotine-induced proliferation of isolated rat pancreatic acinar cells: effect on cell signalling and function. Cell Prolif 40: 125-141, 2007. (Pubitemid 46103695)
89. Dasgupta P, Rizwani W, Pillai S, et al: Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 124: 36-45, 2009.
90. Carlisle DL, Liu X, Hopkins TM, Swick MC, Dhir R and Siegfried JM: Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 20: 629-641, 2007. (Pubitemid 47446337)
91. Murin S and Inciardi J: Cigarette smoking and the risk of pulmonary metastasis from breast cancer. Chest 119: 1635-1640, 2001. (Pubitemid 32744915)
92. Scanlon EF, Suh O, Murthy SM, Mettlin C, Reid SE and Cummings KM: Influence of smoking on the development of lung metastases from breast cancer. Cancer 75: 2693-2699, 1995.
93. Calle EE, Miracle-McMahill HL, Thun MJ and Heath CW Jr: Cigarette smoking and risk of fatal breast cancer. Am J Epidemiol 139: 1001-1007, 1994. (Pubitemid 24156696)
94. Manjer J, Andersson I, Berglund G, et al: Survival of women with breast cancer in relation to smoking. Eur J Surg 166: 852-858, 2000.
95. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK and Yates JW: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285: 885-892, 2001. (Pubitemid 32171549)
96. Videtic GM, Stitt LW, Dar AR, et al: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21: 1544-1549, 2003. (Pubitemid 46594108)
97. Volm M, Samsel B and Mattern J: Relationship between chemoresistance of lung tumours and cigarette smoking. Br J Cancer 62: 255-256, 1990. (Pubitemid 20242446)
98. Browman GP, Wong G, Hodson I, et al: Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328: 159-163, 1993. (Pubitemid 23021501)
99. Chelghoum Y, Danaila C, Belhabri A, et al: Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol 13: 1621-1627, 2002. (Pubitemid 35331461)
100. Johnston-Early A, Cohen MH, Minna JD, et al: Smoking abstinence and small cell lung cancer survival. An association. JAMA 244: 2175-2179, 1980. (Pubitemid 10025379)
101. Costa F and Soares R: Nicotine: a pro-angiogenic factor. Life Sci 84: 785-790, 2009.
102. Heeschen C, Chang E, Aicher A and Cooke JP: Endothelial progenitor cells participate in nicotine-mediated angiogenesis. J Am Coll Cardiol 48: 2553-2560, 2006. (Pubitemid 44881229)
103. Mousa S and Mousa SA: Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem 97: 1370-1378, 2006.
104. Park YJ, Lee T, Ha J, Jung IM, Chung JK and Kim SJ: Effect of nicotine on human umbilical vein endothelial cells (HUVECs) migration and angiogenesis. Vascul Pharmacol 49: 32-36, 2008.
105. Mathur RS, Mathur SP and Young RC: Up-regulation of epidermal growth factor-receptors (EGF-R) by nicotine in cervical cancer cell lines: this effect may be mediated by EGF. Am J Reprod Immunol 44: 114-120, 2000. (Pubitemid 30621334)
106. Chu M, Guo J and Chen CY: Long-term exposure to nicotine, via ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition. J Biol Chem 280: 6369-6379, 2005. (Pubitemid 40341183)
107. Guo J, Chu M, Abbeyquaye T and Chen CY: Persistent nicotine treatment potentiates amplification of the dihydrofolate reductase gene in rat lung epithelial cells as a consequence of Ras activation. J Biol Chem 280: 30422-30431, 2005. (Pubitemid 41216226)
108. Zhang T, Lu H, Shang X, et al: Nicotine prevents the apoptosis induced by menadione in human lung cancer cells. Biochem Biophys Res Commun 342: 928-934, 2006. (Pubitemid 43320486)
109. Al-Wadei HA, Plummer HK III and Schuller HM: Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 30: 506-511, 2009.
110. Al-Wadei HA and Schuller HM: Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. J Pathol 218: 437-445, 2009.
111. Hecht SS, Chen CB, Hirota N, Ornaf RM, Tso TC and Hoffmann D: Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J Natl Cancer Inst 60: 819-824, 1978. (Pubitemid 8331120)
112. Prokopczyk B, Hoffmann D, Bologna M, et al: Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 15: 677-685, 2002. (Pubitemid 34535123)
113. Rivenson A, Hoffmann D, Prokopczyk B, Amin S and Hecht SS: Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 48: 6912-6917, 1988. (Pubitemid 19012226)
114. Hoffmann D, Rivenson A, Abbi R and Wynder EL: A study of tobacco carcinogenesis: effect of the fat content of the diet on the carcinogenic activity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res 53: 2758-2761, 1993. (Pubitemid 23180511)
115. Wang M, Abbruzzese JL, Friess H, et al: DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res 58: 38-41, 1998. (Pubitemid 28027713)
116. Hoffmann D, Rivenson A, Chung FL and Hecht SS: Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogenesis. Crit Rev Toxicol 21: 305-311, 1991.
117. Hecht SS and Hoffmann D: Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 9: 875-884, 1988.
118. Hecht SS: DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res 424: 127-142, 1999.
119. Staretz ME and Hecht SS: Effects of phenethyl isothiocyanate on the tissue distribution of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites in F344 rats. Cancer Res 55: 5580-5588, 1995.
120. Morse MA, Wang CX, Stoner GD, et al: Inhibition of 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone-induced DNA adduct formation and tumorigenicity in the lung of F344 rats by dietary phenethyl isothiocyanate. Cancer Res 49: 549-553, 1989. (Pubitemid 19050313)
121. Van BJ, Feron VJ, Leeman WR, Wilmer JW, Vermeulen E, den Engelse L and Scherer E: Immunocytochemical identification of DNA adducts, O6-methylguanine and 7-methylguanine, in respiratory and other tissues of rat, mouse and Syrian hamster exposed to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 15: 2023-2029, 1994.
122. Baskaran K, Laconi S and Reddy MK: Transformation of hamster pancreatic duct cells by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in vitro. Carcinogenesis 15: 2461-2466, 1994. (Pubitemid 24343676)
123. Kolar C and Lawson T: Mutagenicity of carcinogenic nitrosamines when activated by hamster and human pancreatic duct epithelial cells. Cancer Lett 117: 149-154, 1997. (Pubitemid 27373354)
124. Correa E, Joshi PA, Castonguay A and Schuller HM: The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is an active transplacental carcinogen in Syrian golden hamsters. Cancer Res 50: 3435-3438, 1990. (Pubitemid 20190156)
125. Schuller HM, Jorquera R, Lu X, Riechert A and Castonguay A: Transplacental carcinogenicity of low doses of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone administered subcutaneously or intratracheally to hamsters. J Cancer Res Clin Oncol 120: 200-203, 1994. (Pubitemid 24028557)
126. Schuller HM, Jorquera R, Reichert A and Castonguay A: Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 53: 2498-2501, 1993. (Pubitemid 23168012)
127. Zhang L, Weddle DL, Thomas PE, Zheng B, Castonguay A, Schuller HM and Miller MS: Low levels of expression of cytochromes P-450 in normal and cancerous fetal pancreatic tissues of hamsters treated with NNK and/or ethanol. Toxicol Sci 56: 313-323, 2000. (Pubitemid 30497500)
128. Schulze J, Richter E, Binder U and Zwickenpflug W: Biliary excretion of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the rat. Carcinogenesis 13: 1961-1965, 1992.
129. Peterson LA, Ng DK, Stearns RA and Hecht SS: Formation of NADP(H) analogs of tobacco-specific nitrosamines in rat liver and pancreatic microsomes. Chem Res Toxicol 7: 599-608, 1994. (Pubitemid 24302154)
130. Zhang S, Wang M, Villalta PW, Lindgren BR, Upadhyaya P, Lao Y and Hecht SS: Analysis of pyridyloxobutyl and pyridylhydroxybutyl DNA adducts in extrahepatic tissues of F344 rats treated chronically with 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanone and enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl) -1-butanol. Chem Res Toxicol 22: 926-936, 2009.
131. Schuller HM, Kabalka G, Smith G, Mereddy A, Akula M and Cekanova M: Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention. Chem Med Chem 1: 603-610, 2006. (Pubitemid 44105786)
132. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K and Miller MS: The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 128: 525-532, 2002. (Pubitemid 35244927)
133. Schuller HM, Tithof PK, Williams M and Plummer H, III: The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59: 4510-4515, 1999. (Pubitemid 29428948)
134. Wu WK, Wong HP, Luo SW, et al: 4-(Methylnitrosamino)-1-(3-pyridyl)-1- butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res 65: 5272-5277, 2005. (Pubitemid 40827338)
135. Ye YN, Liu ES, Shin VY, Wu WK and Cho CH: The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther 311: 123-130, 2004. (Pubitemid 39287791)
136. Askari MD, Tsao MS and Schuller HM: The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. J Cancer Res Clin Oncol 131: 639-648, 2005. (Pubitemid 41502206)
137. Laag E, Majidi M, Cekanova M, Masi T, Takahashi T and Schuller HM: NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer 119: 1547-1552, 2006. (Pubitemid 44258759)
138. Schuller HM and Orloff M: Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 55: 1377-1384, 1998. (Pubitemid 28298517)
139. Jull BA, Plummer HK, III and Schuller HM: Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 127: 707-717, 2001.
140. Minna JD: Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest 111: 31-33, 2003.
141. Gahring LC and Rogers SW: Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J 7: E885-E894, 2005.
142. Maneckjee R and Minna JD: Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 5: 1033-1040, 1994. (Pubitemid 24312278)
143. Arredondo J, Chernyavsky AI and Grando SA: The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells. J Cancer Res Clin Oncol 132: 653-663, 2006. (Pubitemid 44310331)
144. Arredondo J, Chernyavsky AI and Grando SA: Nicotinic receptors mediate tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells. Cancer Biol Ther 5: 511-517, 2006. (Pubitemid 43765286)
145. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE and Grando SA: Receptor-mediated tobacco toxicity: alterations of the NF-kappaB expression and activity downstream of alpha7 nicotinic receptor in oral keratinocytes. Life Sci 80: 2191-2194, 2007. (Pubitemid 46824132)
146. Xu L and Deng X: Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion. J Biol Chem 279: 53683-53690, 2004. (Pubitemid 40051876)
147. Jin Z, Gao F, Flagg T and Deng X: Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 279: 40209-40219, 2004. (Pubitemid 39258297)
148. Pour P, Althoff J, Kruger FW and Mohr U: Improvement of pancreatic cancer model by modified treatment with N-nitroso-bis (2-oxopropyl) amine. Cancer Lett 2: 233-237, 1977.
149. Grippo PJ and Sandgren EP: Modeling pancreatic cancer in animals to address specific hypotheses. Methods Mol Med 103: 217-243, 2005.
150. Furukawa F, Nishikawa A, Yoshimura H, Mitsui M, Imazawa T, Ikezaki S and Takahashi M: Effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) on N-nitrosobis(2-oxopropyl)amine (BOP)-initiated carcinogenesis in hamsters. Cancer Lett 86: 75-82, 1994. (Pubitemid 24318985)
151. Furukawa F, Nishikawa A, Enami T, et al: Promotional effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) on N-nitrosobis(2- oxopropyl)amine (BOP)-initiated carcinogenesis in hamsters. Food Chem Toxicol 35: 387-392, 1997. (Pubitemid 27266013)
152. Kimura K, Satoh K, Kanno A, et al: Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci 98: 155-162, 2007. (Pubitemid 44941866)
153. Osvaldt AB, Wendt LR, Bersch VP, Backes AN, de Cassia AS, Edelweiss MI and Rohde L: Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice. Surgery 140: 803-809, 2006. (Pubitemid 44754985)
154. Rivera JA, Graeme-Cook F, Werner J, et al: A rat model of pancreatic ductal adenocarcinoma: targeting chemical carcinogens. Surgery 122: 82-90, 1997. (Pubitemid 27295171)
155. Jimenez RE, Z'graggen K, Hartwig W, Graeme-Cook F, Warshaw AL and Fernandez-del CC: Immunohistochemical characterization of pancreatic tumors induced by dimethylbenzanthracene in rats. Am J Pathol 154: 1223-1229, 1999. (Pubitemid 29169756)
156. Sperti C, Militello C, Rovati L, et al: Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat. J Surg Oncol 57: 11-16, 1994. (Pubitemid 24274868)
157. Matsuno S, Ejiri T, Kobari M, Yamauchi H and Sato T: Effects of immunosuppressive acidic protein on DMBA-induced pancreatic cancer in rats. Tohoku J Exp Med 144: 189-202, 1984. (Pubitemid 15175674)
158. Black O Jr, Murrill E and Fanska C: Metabolism of a carcinogen (7,12-dimethylbenzanthracene) in the pancreas of the Long-Evans rat. Res Commun Chem Pathol Pharmacol 33: 103-118, 1981. (Pubitemid 11010343)
159. Bockman DE, Black O Jr, Mills LR and Webster PD: Origin of tubular complexes developing during induction of pancreatic adenocarcinoma by 7,12-dimethylbenz(a)anthracene. Am J Pathol 90: 645-658, 1978. (Pubitemid 8285892)
160. Rao MS and Reddy JK: Histogenesis of pseudo-ductular changes induced in the pancreas of guinea pigs treated with N-methyl-N-nitrosourea. Carcinogenesis 1: 1027-1037, 1980. (Pubitemid 11185509)
161. Carriere C, Seeley ES, Goetze T, Longnecker DS and Korc M: The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci USA 104: 4437-4442, 2007. (Pubitemid 47186244)
162. Zhu L, Shi G, Schmidt CM, Hruban RH and Konieczny SF: Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 171: 263-273, 2007. (Pubitemid 47339243)
163. Guerra C, Schuhmacher AJ, Canamero M, et al: Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302, 2007. (Pubitemid 46349841)
164. Strobel O, Dor Y, Stirman A, Trainor A, Fernandez-del CC, Warshaw AL and Thayer SP: Beta cell transdifferentiation does not contribute to preneoplastic/metaplastic ductal lesions of the pancreas by genetic lineage tracing in vivo. Proc Natl Acad Sci USA 104: 4419-4424, 2007. (Pubitemid 47186241)
165. Strobel O, Dor Y, Alsina J, et al: In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 133: 1999-2009, 2007. (Pubitemid 350180811)
166. Habbe N, Shi G, Meguid RA, et al: Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA 105: 18913-18918, 2008.
167. Gingell R, Wallcave L, Nagel D, Kupper R and Pour P: Metabolism of the pancreatic carcinogens N-nitroso-bis(2-oxopropyl)amine and N-nitroso-bis(2- hydroxypropyl)amine in the Syrian hamster. J Natl Cancer Inst 57: 1175-1178, 1976.
168. Lijinsky W, Saavedra JE and Kovatch RM: Carcinogenesis and nucleic acid alkylation by some oxygenated nitrosamines in rats and hamsters. Chem Biol Interact 66: 37-47, 1988.
169. Satake K, Umeyama K, Kamino K, Uchima K and Yamashita K: Pancreatic cancer developing in Sprague-Dawley rats after local application of 7,12-dimethyl benzanthracene (DMBA). Osaka City Med J 21: 119-126, 1975.
170. Satake K, Mukai R, Kato Y, Shim K and Umeyama K: Experimental pancreatic carcinoma as a model of human pancreatic carcinoma. Clin Oncol 10: 27-34, 1984. (Pubitemid 14156962)
171. Lijinsky W, Reuber MD and Reznik-Schuller HM: Contrasting carcinogenic effects of nitroso-2,6-dimethylmorpholine given by gavage to F344 rats and Syrian golden hamsters. Cancer Lett 16: 281-286, 1982. (Pubitemid 12036322)
172. Kokkinakis DM and Scarpelli DG: Carcinogenicity of N-nitroso(2- hydroxypropyl)(2-oxopropyl)amine, N-nitrosobis(2-hydroxypropyl)amine and cis-N-nitroso-2,6-dimethylmorpholine administered continuously in the Syrian hamster, and the effect of dietary protein on N-nitroso(2-hydroxypropyl)(2- oxopropyl)amine carcinogenesis. Carcinogenesis 10: 699-704, 1989. (Pubitemid 19101287)
173. Pour P, Gingell R, Langenbach R, Nagel D, Grandjean C, Lawson T and Salmasi S: Carcinogenicity of N-nitrosomethyl(2-oxopropyl)amine in Syrian hamsters. Cancer Res 40: 3585-3590, 1980. (Pubitemid 10003755)
174. Cullingworth J, Hooper ML, Harrison DJ, Mason JO, Sirard C, Patek CE and Clarke AR: Carcinogen-induced pancreatic lesions in the mouse: effect of Smad4 and Apc genotypes. Oncogene 21: 4696-4701, 2002. (Pubitemid 34833147)
175. Reddy JK and Rao MS: Pancreatic adenocarcinoma in inbred guinea pigs induced by n-methyl-N-nitrosourea. Cancer Res 35: 2269-2277, 1975.
176. Shirai T, Kato K, Futakuchi M, Takahashi S, Suzuki S, Imaida K and Asamoto M: Organ differences in the enhancing potential of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine on carcinogenicity in the prostate, colon and pancreas. Mutat Res 506-507: 129-136, 2002. (Pubitemid 35286547)
177. Zhu J, Rashid A, Cleary K, et al: Detection of 2-amino-1-methyl-6- phenylimidazo [4,5-b]-pyridine (PhIP)-DNA adducts in human pancreatic tissues. Biomarkers 11: 319-328, 2006.
178. Elkort RJ, Handler AH and Williams DL: Early neoplasia of rabbit pancreatic ductal cells induced dimethylhydrazine. Cancer Res 35: 2292-2294, 1975.